A survey of 300 gastroenterologistsa confirms the benefits of MiraLAX®¹

More than 9 out of 10 GIs said that a balance of efficacy and tolerability was the most important consideration in choosing a first-line OTC occasional constipation (OC) treatment for adult patientsa,b


purple doctor person icons - 9 dark purple and 1 light purple showing 9 out of 10 doctors

 

aBased on a survey that asked 300 gastroenterologists to rate the important factors in choosing an OTC medication for adults with occasional constipation and how well MiraLAX® met those needs. HCPs selected from a set of options based on their clinical experience. Survey details and data are available upon request.
b93% rated the strength of their belief in the importance of this consideration ≥5 on a scale of 1-7.

3 out of 4 GIs rated occasional constipation as having a negative impact on their patients’ quality of lifea,c

Miralax purple icon of person with pain at digestive system

  • In another survey, ~70% of people with OC had difficulty working, and at least 1 in 10 people missed work completely due to constipation2,d

c75% of GIs rated the degree of negative impact ≥5 on a scaled of 1-7.1
dBased on a survey of 557 patients in the Knowledge Networks Panel who reported chronic constipation.2

Miralax purple icon stating 90% of GIs

 

said MiraLAX® is “the OTC laxative that best balances efficacy and tolerability” and is the one they “trust the most”1,a,e

 

eGIs rated the strength of their agreement with these statements ≥5 on a scale of 1-7.

More than two-thirds of GIs said

water icon for hydration, water cloud and leaf icons for stool softening and wavy lines icon for gentle peristalsis

 

are the most important mechanisms for an OC treatment and that MiraLAX® provides these more effectively than other OTC laxatives1,a

Miralax purple icon stating 3X more of GIs and 14X more GIs

 

 

When choosing a first-line over-the-counter OC treatment:

  • Nearly 9 out of 10 GIs said avoiding gas and bloating is their most important consideration1,a,f

Nearly 8 out of 10 GIs said avoiding colonic nerve stimulation is a top consideration1,a,g

95% of GIs rated MiraLAX® highest for tolerability at an effective dose vs other OTC brands1,a,h

f87% rated the strength of their belief in the importance of this consideration ≥5 on a scale of 1-7.
g79% rated the strength of their belief in the importance of this consideration ≥5 on a scale of 1-7.
hGIs rated this benefit of MiraLAX® ≥5 on a scale of 1-7.

 

 

3 different purple circle icons for facts about Miralax
Expand All Collapse All
    References

    References: 1. Data on file, Bayer Healthcare. 2. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608. doi:10.1111/j.1365-2036.2006.03238.x